Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Nektar, AMD, Esperion, and More: Here’s Why These Five Stocks Are Surging

Esperion Therapeutics Inc (NASDAQ:ESPR) shareholders are pretty happy today after the company announced that the FDA recently confirmed that ‘Esperion’s LDL-C lowering program is adequate to support approval of an LDL-C lowering indication for bempedoic acid’. The company continues to plan to submit a NDA by the first half of 2019 for n LDL-C lowering indication based on the successful completion of the global pivotal Phase 3 program. Although many analysts expected this news and approval is still years away, shares of the stock have rallied 50% anyway. The number of elite funds with holdings in Esperion Therapeutics Inc (NASDAQ:ESPR) fell by 4 quarter-over-quarter to 8 at the end of December.

Follow Esperion Therapeutics Inc. (NASDAQ:ESPR)
Trade (NASDAQ:ESPR) Now!

Alibaba Group Holding Ltd (NYSE:BABA) shares have popped 2% due to technical buying today. Sentiment around Chinese internet stocks has improved as the previously frothy relationship between the U.S. and China looks to thaw as the two nations work toward resolving the North Korean nuclear issue. Recently Secretary of State Rex Tillerson met with the Chinese President, and President Trump is expected to meet with Xi Jinping soon as well. If the Chinese-U.S. relationship improves, the risk of a damaging trade war is lower. 86 top funds were long Alibaba Group Holding Ltd (NYSE:BABA) as of the most recent 13-F reporting period, down 18 funds from the previous quarter.

Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) has rallied almost 6% after the company reported positive efficacy data from its Phase 3 TONES 3 and TONES 4 studies. The studies analyzed JZP-110 for potential treatment of the excessive sleepiness symptom associated with obstructive sleep apnea. Gary Nachman of BMO Capital reiterates that Jazz is a ‘top pick’ and feels the data substantially de-risks the program. 34 top funds were long Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) at the end of December, down 7 funds from the previous quarter.

Follow Jazz Pharmaceuticals Plc (NASDAQ:JAZZ)
Trade (NASDAQ:JAZZ) Now!